Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Eli Lilly and Company has revealed positive topline results from the Phase III trials of efsitora alfa to treat adults with ...

Patients may have trouble finding two different types of insulin products made by Eli Lilly. The company said it's experiencing ... with a prefilled pen — or "KwikPen" — over their usual vials to ...

As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the ...

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and ...

The original concerns of the US regulatory agency over the manufacturing of Eli Lilly’s Ebglyss seem to have been resolved, ...

Physicians and health professionals from around the country demanded that Novo Nordisk and Eli Lilly make their novel diabetes and obesity medications affordable and accessible to all.